{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:11:57Z","timestamp":1790331117153,"version":"4.1.0"},"reference-count":27,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Esophageal cancer remains a leading cause of cancer-related mortality worldwide, with docetaxel, cisplatin, and fluorouracil (DCF) chemotherapy being a standard treatment option for locally advanced disease. However, DCF is associated with a high incidence of febrile neutropenia (FN), a serious complication that can lead to treatment delays, hospitalizations, and increased morbidity. Pegfilgrastim, a long-acting granulocyte colony-stimulating factor (G-CSF), is recommended for FN prevention, but its efficacy in esophageal cancer patients receiving DCF chemotherapy remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature search of PubMed, Cochrane Library, Scopus, and Web of Science identified eligible studies. Retrospective and prospective studies comparing prophylactic pegfilgrastim with placebo or no G-CSF in patients undergoing DCF therapy were included. Eight reviewers independently screened studies, extracted data, and assessed quality using the Newcastle\u2013Ottawa Scale. The extracted data were then verified by two additional reviewers. A meta-analysis was conducted to calculate pooled effect sizes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Pooled analysis showed that\n                      <jats:bold>pegfilgrastim significantly reduced FN incidence<\/jats:bold>\n                      (OR =\n                      <jats:bold>0.283<\/jats:bold>\n                      , 95% CI:\n                      <jats:bold>0.102\u20130.782<\/jats:bold>\n                      ,\n                      <jats:bold>p<\/jats:bold>\n                      \u2009\n                      <jats:bold>=<\/jats:bold>\n                      \u2009\n                      <jats:bold>0.015<\/jats:bold>\n                      ). FN rates ranged from\n                      <jats:bold>3.3% to 30.8%<\/jats:bold>\n                      in the pegfilgrastim group versus\n                      <jats:bold>26.7% to 60.6%<\/jats:bold>\n                      in the control group. Pegfilgrastim was also associated with\n                      <jats:bold>lower rates of severe neutropenia and shorter hospital stays<\/jats:bold>\n                      , with no significant increase in adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In our study, Pegfilgrastim prophylaxis significantly reduces FN risk, severe neutropenia, and hospital stays in esophageal cancer patients receiving DCF chemotherapy, without increasing major complications. These findings support its routine use in this population, though further prospective randomized trials are needed to optimize dosing strategies and confirm long-term benefits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261416090","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T18:36:47Z","timestamp":1769711807000},"page":"1370-1379","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of pegfilgrastim in preventing febrile neutropenia during DCF chemotherapy for esophageal cancer: A systematic review and meta-analysis"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2376-1622","authenticated-orcid":false,"given":"Khaled","family":"Hemdan","sequence":"first","affiliation":[{"name":"October 6 University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3431-6796","authenticated-orcid":false,"given":"Rana Mohamed","family":"El Tabakh","sequence":"additional","affiliation":[{"name":"Tanta University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2369-7494","authenticated-orcid":false,"given":"Ziad W","family":"Elmezayen","sequence":"additional","affiliation":[{"name":"Kafr Elsheikh University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7529-0645","authenticated-orcid":false,"given":"Amr Mahmoud","family":"Yousef","sequence":"additional","affiliation":[{"name":"Benha University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1042-5995","authenticated-orcid":false,"given":"Ahmed","family":"Hussein","sequence":"additional","affiliation":[{"name":"Al-azher University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4762-6536","authenticated-orcid":false,"given":"Ali M","family":"Elghareab","sequence":"additional","affiliation":[{"name":"Tanta University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2439-0689","authenticated-orcid":false,"given":"Mazen Momtaz","family":"Shehata","sequence":"additional","affiliation":[{"name":"Modern University for Technology and Information University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa Abdelaziz","family":"Ellethey","sequence":"additional","affiliation":[{"name":"Tanta University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9686-7758","authenticated-orcid":false,"given":"Ahmed","family":"Oun","sequence":"additional","affiliation":[{"name":"Tanta University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.08.023"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1314530"},{"key":"e_1_3_3_4_2","first-page":"394","article-title":"Advances in esophageal cancer treatment","volume":"68","author":"Bray F","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, et al. Advances in esophageal cancer treatment. CA Cancer J Clin 2018; 68(6): 394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"e_1_3_3_5_2","first-page":"2074","article-title":"DCF Chemotherapy for esophageal cancer","volume":"366","author":"Ando N","year":"2012","unstructured":"Ando N, Iizuka T, Kakegawa T, et al. DCF Chemotherapy for esophageal cancer. N Engl J Med 2012; 366: 2074\u20132084.","journal-title":"N Engl J Med"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112088"},{"key":"e_1_3_3_7_2","first-page":"383","article-title":"Comparison of CF vs. DCF in esophageal cancer","volume":"39","author":"Katada C","year":"2021","unstructured":"Katada C, Yokoyama T, Yano M, et al. Comparison of CF vs. DCF in esophageal cancer. J Clin Oncol 2021; 39: 383\u2013393.","journal-title":"J Clin Oncol"},{"key":"e_1_3_3_8_2","first-page":"501","article-title":"Incidence of febrile neutropenia in DCF","volume":"33","author":"Hironaka S","year":"2015","unstructured":"Hironaka S, Ueda S, Yasui H, et al. Incidence of febrile neutropenia in DCF. J Clin Oncol 2015; 33(6): 501\u2013507.","journal-title":"J Clin Oncol"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3488"},{"key":"e_1_3_3_10_2","first-page":"1466","article-title":"Efficacy of pegfilgrastim in chemotherapy","volume":"23","author":"Crawford J","year":"2018","unstructured":"Crawford J, Becker PS, Armitage JO, et al. Efficacy of pegfilgrastim in chemotherapy. Oncologist 2018; 23: 1466\u20131473.","journal-title":"Oncologist"},{"key":"e_1_3_3_11_2","first-page":"829","article-title":"Introduction of pegfilgrastim in Japan","volume":"45","author":"Kondo K","year":"2015","unstructured":"Kondo K, Tahara M, Nakagawa K, et al. Introduction of pegfilgrastim in Japan. Jpn J Clin Oncol 2015; 45: 829\u2013835.","journal-title":"Jpn J Clin Oncol"},{"key":"e_1_3_3_12_2","first-page":"194","article-title":"Pegfilgrastim in breast cancer","volume":"30","author":"Lalami Y","year":"2016","unstructured":"Lalami Y, Klastersky J, Aapro M. Pegfilgrastim in breast cancer. Breast 2016; 30: 194\u2013200.","journal-title":"Breast"},{"key":"e_1_3_3_13_2","first-page":"285","article-title":"Pegfilgrastim in esophageal cancer","volume":"50","author":"Suzuki T","year":"2020","unstructured":"Suzuki T, Kato R, Hashimoto N, et al. Pegfilgrastim in esophageal cancer. Jpn J Clin Oncol 2020; 50: 285\u2013292.","journal-title":"Jpn J Clin Oncol"},{"key":"e_1_3_3_14_2","first-page":"1825","article-title":"Timing of pegfilgrastim administration","volume":"27","author":"Yamamoto K","year":"2019","unstructured":"Yamamoto K, Ando N, Yamashita K, et al. Timing of pegfilgrastim administration. Support Care Cancer 2019; 27: 1825\u20131831.","journal-title":"Support Care Cancer"},{"key":"e_1_3_3_15_2","unstructured":"Wells GA Shea B O'Connell D et al. The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa Hospital Research Institute https:\/\/doi.org\/10.13140\/RG.2.1.1158.4485 (2011)."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15758"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.21037\/aoe-24-20"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.31083\/ph.2018.8576"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.16393"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-018-1306-3"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-019-1665-x"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-010-0816-y"},{"key":"e_1_3_3_23_2","first-page":"3019","article-title":"Efficacy of pegfilgrastim to support neoadjuvant dose-dense epirubicin and cyclophosphamide chemotherapy in breast cancer","volume":"27","author":"Wang X","year":"2019","unstructured":"Wang X, He Y, Wang T, et al. Efficacy of pegfilgrastim to support neoadjuvant dose-dense epirubicin and cyclophosphamide chemotherapy in breast cancer. Support Care Cancer 2019 Aug; 27: 3019\u20133025. Epub 2019 Jan 4. PMID: 30607682.","journal-title":"Support Care Cancer"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg019"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2021.1168"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.16119"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(03)00314-2"},{"key":"e_1_3_3_28_2","first-page":"106","article-title":"Systemic treatment-induced gastrointestinal toxicity: Incidence, clinical presentation and management","volume":"25","author":"Boussios S","year":"2012","unstructured":"Boussios S, Pentheroudakis G, Katsanos K, et al. Systemic treatment-induced gastrointestinal toxicity: Incidence, clinical presentation and management. Ann Gastroenterol 2012; 25: 106\u2013118. PMID: 24713845; PMCID: PMC3959393.","journal-title":"Ann Gastroenterol"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261416090","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261416090","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261416090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:57:08Z","timestamp":1790330228000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261416090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/10781552261416090"],"URL":"https:\/\/doi.org\/10.1177\/10781552261416090","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]}}}